Sign in
Taking people in JapanNo phase

Long-term safety survey of AJOVY injection for migraine in routine use

Observes long-term safety of fremanezumab injection in adults with migraine.

Key facts

Who runs it
Otsuka Pharmaceutical Co., Ltd.
Where
Osaka, JapanSee the site
Trial code
Registry title
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Status
Recruiting
People taking part
1,000 people, planned
Started
20 Apr 2022
Expected to end
22 Jun 2029
Type of study
Observational
Treatments tested
  • Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
Record updated
22 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with migraine who use AJOVY (fremanezumab) injections, to follow long-term safety in real-life use.

Age
18 years and older
Sex
All sexes can join.

Main reasons for not taking part

  • Known hypersensitivity (allergy) to components of AJOVY

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • -

Who cannot take part

  • patients with a known hypersensitivity to components of AJOVY

Where in Japan

  • Pharmacovigilance DepartmentOsaka, JapanContact: Satoshi Komaniwa, PhDTaking people

About the trial

What the trial wants to find out

To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.

The group in the trial

  • Drug

    Ajovy syringe for SC injection 225 mg.

    Treatment: Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
AJOVY Subcutaneous Injection Long-term Specified Use-results Survey
Plain-language title
Long-term safety survey of AJOVY injection for migraine in routine useGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 June 2026